In this scenario, chemotherapeutics may elicit TP53-dependent cell cycle arrest in part via induction of p21, which has been demonstrated to occur in luminal breast tumors after neoadjuvant chemotherapy [39]. The gene discussed is TP53; the disease is breast neoplasm.